Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
复制标题
DOI：
10.1056/nejmoa1010949
复制
发表时间：
2011-03-24
影响因子：
158.5
通讯作者：
Reaven, Peter D.
中科院分区：
文献类型：
--
作者：
DeFronzo, Ralph A.;Tripathy, Devjit;Reaven, Peter D.
背景糖耐量受损与心血管疾病和2型糖尿病转化率增加有关。干预措施，可以防止或延迟这种情况是非常重要的临床important. METHODS我们进行了一项随机，双盲，安慰剂对照研究，以检查是否吡格列酮可以降低2型糖尿病的风险，在成人糖耐量受损。共有602例患者被随机分配接受吡格列酮或安慰剂治疗。中位随访期为2.4年。每季度测量一次空腹血糖，每年进行一次口服葡萄糖耐量试验。2型糖尿病的年发病率吡格列酮组为2.1%，安慰剂组为7.6%，吡格列酮组转化为糖尿病的危险比为0.28（95%可信区间为0.16 - 0.49; P
BACKGROUNDImpaired glucose tolerance is associated with increased rates of cardiovascular disease and conversion to type 2 diabetes mellitus. Interventions that may prevent or delay such occurrences are of great clinical importance.METHODSWe conducted a randomized, double-blind, placebo-controlled study to examine whether pioglitazone can reduce the risk of type 2 diabetes mellitus in adults with impaired glucose tolerance. A total of 602 patients were randomly assigned to receive pioglitazone or placebo. The median follow-up period was 2.4 years. Fasting glucose was measured quarterly, and oral glucose tolerance tests were performed annually. Conversion to diabetes was confirmed on the basis of the results of repeat testing.RESULTSAnnual incidence rates for type 2 diabetes mellitus were 2.1% in the pioglitazone group and 7.6% in the placebo group, and the hazard ratio for conversion to diabetes in the pioglitazone group was 0.28 (95% confidence interval, 0.16 to 0.49; P